Trends in Patent Ductus Arteriosus Diagnosis and Management for Very Low Birth Weight Infants
- PMID: 28562302
- PMCID: PMC5369670
- DOI: 10.1542/peds.2016-2390
Trends in Patent Ductus Arteriosus Diagnosis and Management for Very Low Birth Weight Infants
Abstract
Objective: To examine yearly trends of patent ductus arteriosus (PDA) diagnosis and treatment in very low birth weight infants.
Methods: In this retrospective cohort study of very low birth weight infants (<1500 g) between 2008 and 2014 across 134 California hospitals, we evaluated PDA diagnosis and treatment by year of birth. Infants were either inborn or transferred in within 2 days after delivery and had no congenital abnormalities. Intervention levels for treatment administered to achieve ductal closure were categorized as none, pharmacologic (indomethacin or ibuprofen), both pharmacologic intervention and surgical ligation, or ligation only. Multivariable logistic regression was used to assess risk factors for PDA diagnosis and treatment.
Results: PDA was diagnosed in 42.8% (12 002/28 025) of infants, with a decrease in incidence from 49.2% of 4205 infants born in 2008 to 38.5% of 4001 infants born in 2014. Pharmacologic and/or surgical treatment was given to 30.5% of patients. Between 2008 and 2014, the annual rate of infants who received pharmacologic intervention (30.5% vs 15.7%) or both pharmacologic intervention and surgical ligation (6.9% vs 2.9%) decreased whereas infants who were not treated (60.5% vs 78.3%) or received primary ligation (2.2% vs 3.0%) increased.
Conclusions: There is an increasing trend toward not treating patients diagnosed with PDA compared with more intensive treatments: pharmacologic intervention or both pharmacologic intervention and surgical ligation. Possible directions for future study include the impact of these trends on hospital-based and long-term outcomes.
Copyright © 2017 by the American Academy of Pediatrics.
Conflict of interest statement
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
Figures





Similar articles
-
Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants.J Neonatal Perinatal Med. 2014 Jan 1;7(3):229-35. doi: 10.3233/NPM-14814015. J Neonatal Perinatal Med. 2014. PMID: 25322995
-
Hospital variation in medical and surgical treatment of patent ductus arteriosus.Am J Perinatol. 2015 Mar;32(4):379-86. doi: 10.1055/s-0034-1387931. Epub 2014 Sep 21. Am J Perinatol. 2015. PMID: 25241108
-
Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus.Pediatr Res. 2016 Dec;80(6):785-792. doi: 10.1038/pr.2016.166. Epub 2016 Aug 10. Pediatr Res. 2016. PMID: 27509008
-
Treatment of patent ductus arteriosus: indomethacin or ibuprofen?J Perinatol. 2008 May;28 Suppl 1:S60-2. doi: 10.1038/jp.2008.52. J Perinatol. 2008. PMID: 18446180 Review.
-
[Ibuprofen--a new application for pharmacological closure of patent ductus arteriosus in preterm infants. Preliminary report].Med Wieku Rozwoj. 2000;4(2 Suppl 3):65-71. Med Wieku Rozwoj. 2000. PMID: 11328971 Review. Polish.
Cited by
-
Changing patterns of patent ductus arteriosus surgical ligation in the United States.Semin Perinatol. 2018 Jun;42(4):253-261. doi: 10.1053/j.semperi.2018.05.008. Epub 2018 May 22. Semin Perinatol. 2018. PMID: 29954594 Free PMC article. Review.
-
Multi-centre, randomised non-inferiority trial of early treatment versus expectant management of patent ductus arteriosus in preterm infants (the BeNeDuctus trial): statistical analysis plan.Trials. 2021 Sep 15;22(1):627. doi: 10.1186/s13063-021-05594-x. Trials. 2021. PMID: 34526095 Free PMC article. Clinical Trial.
-
Spontaneous Closure of the Ductus Arteriosus in Preterm Infants: A Systematic Review.Front Pediatr. 2020 Sep 11;8:541. doi: 10.3389/fped.2020.00541. eCollection 2020. Front Pediatr. 2020. PMID: 33014935 Free PMC article.
-
Efficacy and safety of systemic hydrocortisone for the prevention of bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis.Eur J Pediatr. 2019 Aug;178(8):1171-1184. doi: 10.1007/s00431-019-03398-5. Epub 2019 May 29. Eur J Pediatr. 2019. PMID: 31144162 Free PMC article.
-
Factors Associated With Benefit of Treatment of Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-Analysis.Front Pediatr. 2021 Feb 9;9:626262. doi: 10.3389/fped.2021.626262. eCollection 2021. Front Pediatr. 2021. PMID: 33634058 Free PMC article.
References
-
- Schena F, Francescato G, Cappelleri A, et al. . Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia. J Pediatr. 2015;166(6):1488–1492 - PubMed
-
- Noori S, McCoy M, Friedlich P, et al. . Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics. 2009;123(1). Available at: www.pediatrics.org/cgi/content/full/123/1/e138 - PubMed
-
- Dollberg S, Lusky A, Reichman B. Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr. 2005;40(2):184–188 - PubMed
-
- Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O’Shea TM; North Carolina Neonatologists Association . Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. Pediatrics. 1999;104(6):1345–1350 - PubMed
-
- Jain A, Shah PS. Diagnosis, evaluation, and management of patent ductus arteriosus in preterm neonates. JAMA Pediatr. 2015;169(9):863–872 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources